Ab&b Bio-Tech’s Trivalent Influenza Vaccine Wins NMPA Nod for All Ages

Ab&b Bio-Tech Co.,Ltd. (HKG: 2627) announced that the National Medical Products Administration (NMPA) has granted marketing approval for its trivalent influenza virus subunit vaccine for all age groups, making it the first and only trivalent influenza subunit vaccine approved in China across the full age spectrum at full dosage.

Regulatory Milestone & Product Profile

Market Impact & Commercial Outlook

• China Influenza Vaccine Market: Valued at ¥12 billion : (~US$1.7 billion) in 2025, growing at 8% CAGR driven by expanded immunization programs and public awareness
• Subunit Vaccine Segment: Represents ~15% : of market but growing faster than traditional split‑virus vaccines due to superior safety and efficacy profiles
• First‑Mover Advantage: Ab&b’s approval creates 12‑month market exclusivity in trivalent subunit category, commanding premium pricing
• Public Health Impact: Universal age indication simplifies procurement for national immunization programs and private market distribution
• Manufacturing Scale: Company’s existing GMP facilities can support 30 million+ doses annually, positioning for significant market share capture
• Revenue Potential: Analysts project ¥2.5–4.0 billion (US$350–560 million) peak annual sales by 2029, assuming 20% penetration of trivalent vaccine segment

Forward‑Looking Statements
This brief contains forward‑looking statements regarding market penetration, revenue projections, and manufacturing capacity for Ab&b Bio-Tech’s influenza vaccine. Actual results may differ due to competitive responses, regulatory changes, and market adoption rates.-Fineline Info & Tech